ClinicalTrials.gg
CompletedNCT05486117Updated Apr 4, 2025

Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema

A Phase 1 interventional study of Delgocitinib in Chronic Hand Eczema, sponsored by LEO Pharma. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by LEO Pharma · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Eczema by LEO Pharma — 1 open to participants now, 1 under way, none of them phase 3. Eczema · LEO Pharma.

Enrollment
12th of 12
15 · median 178
Started
2022
with 2 others
Phase 1
2 of 13
none open now
Registered
11th of 13
by date

Among the 13 studies in Eczema by LEO Pharma, this one is the 12th largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2022, is one of 2 in phase 1, and was the 11th registered.

Eczema

506 studies on the registry are indexed under Eczema; 90 are open to participants now.

Browse Eczema studies →

Open to participants now

1 of the 13 studies in Eczema by LEO Pharma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 66 Eczema studies recruiting now, 31 (47%) set no upper age limit and 27 (41%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Eczema by LEO Pharma, or all of them as a file.
02

Study summary

The purpose of the trial is to test how much delgocitinib enters the body over a given time period after application of delgocitinib cream in patients with moderate to severe hand eczema.

Delgocitinib is a cream that suppresses specific processes in the body's response to diseases like CHE, such as inflammation. Everyone in the trial will use delgocitinib cream.

The trial will last up to 7 weeks and there will be 6 visits and a phone call. There will be a screening period of up to 4 weeks, a treatment period (with blood sampling) of 11 days and a safety follow-up phone call 11 days after the last visit.

03

Conditions studied

  • Chronic Hand Eczema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or above at screening.
  • Diagnosis of CHE, defined as hand eczema that has persisted for more than 3 months or returned twice or more within the last 12 months.
  • Disease severity graded as moderate to severe at screening and baseline according to IGA-CHE (i.e. an IGA-CHE score of 3 or 4).
  • Subjects who have a documented recent history of inadequate response to treatment with topical (TCS) (at any time within 1 year before the screening visit) or for whom TCS are documented to be otherwise medically inadvisable (e.g. due to important side effects or safety risks).
  • Subjects adherent to standard non-medicated skin care including avoidance of known and relevant irritants and allergens.

Exclusion criteria

Exclusion Criteria:

  • Concurrent skin diseases on the hands, e.g. tinea manuum.
  • Active atopic dermatitis (AD) requiring medical treatment in regions other than the hands and feet.
  • Active psoriasis on any part of the body.
  • Hyperkeratotic hand eczema in combination with a history of psoriasis on any part of the body.
  • infection (e.g. impetiginised hand eczema) on the hands.
  • Systemic treatment with drugs (e.g. methotrexate, cyclosporine, azathioprine), immunomodulating drugs, retinoids (e.g. alitretinoin), or within 28 days prior to baseline (steroid eyedrops and inhaled or intranasal steroids corresponding to up to 1 mg prednisolone for allergic conjunctivitis, asthma, or rhinitis are allowed).
  • Use of tanning beds, phototherapy (e.g. ultraviolet B [UVB], ultraviolet A1 [UVA1], psoralen ultraviolet A [PUVA]), or bleach baths on the hands within 28 days prior to baseline.
  • Cutaneously applied treatment with immunomodulators (e.g. phosphodiesterase 4 [PDE-4] inhibitors, pimecrolimus, tacrolimus) or TCS on the hands within 14 days prior to baseline.
  • Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 14 days prior to baseline.
  • Cutaneously applied treatments in regions other than the hands, which could interfere with clinical trial evaluations or pose a safety concern within 7 days prior to baseline.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Delgocitinib cream 20 mg/g

    Twice-daily topical application for 8 days

    Drug: Delgocitinib

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve 0-12 hours post dose at Day 1 and Day 8 (AUC0-12).

    Time frame: 0-12 hours post dose at Day 1 and Day 8

  2. Maximum observed concentration (Cmax) at Day 1 and at Day 8 (0-12 hours post-dose).

    Time frame: Day 1 and at Day 8 (0-12 hours post-dose)

Secondary outcomes

  1. Time to reach maximum observed concentration (tmax) at Day 1 and Day 8 (0-12 hours post-dose).

    Time frame: Day 1 and Day 8 (0-12 hours post-dose).

  2. Terminal elimination half-life (t1/2) at Day 8.

    Time frame: Day 8.

  3. Number of treatment-emergent adverse events (AEs) from baseline to Day 22 per subject.

    Time frame: Baseline to Day 22

07

Study locations

1 site
  • LEO Investigational Site
    Hamburg, 20095, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Nov 2022, 2 months.

Of 16 phase 1 interventional studies under Eczema, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2022
First posted
Aug 3, 2022
StartActual
Sep 6, 2022
Primary completionActual
Nov 22, 2022
CompletionActual
Nov 22, 2022
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05486117
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Aug 3, 2022
Start date
Sep 6, 2022
Primary completion
Nov 22, 2022
Completion
Nov 22, 2022
Last update
Apr 4, 2025

Study contacts

Medical Expert
study director · LEO Pharma

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delgocitinib

Start the discussion